Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Coeur Commences Drilling at Silver North's Tim Project (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Delcath Systems Inc DCTH

Healthcare Medical Devices Diagnostics & Research
Delcath Systems, Inc. is an interventional oncology company focused on the treatment of primary and metastatic liver cancers. The Company's products, HEPZATO KIT (Hepzato (melphalan) for Injection/Hepatic Delivery System) and CHEMOSAT Hepatic Delivery System for Melphalan (CHEMOSAT) percutaneous hepatic perfusion (PHP) are designed to administer high-dose chemotherapy to the liver while... see more

Recent & Breaking News (NDAQ:DCTH)

Delcath Issues Letter to Stockholders

GlobeNewswire August 17, 2018

Delcath Announces Second Quarter Fiscal 2018 Financial Results

GlobeNewswire August 15, 2018

Delcath Announces Commencement of Rights Offering Subscription Period

GlobeNewswire August 6, 2018

Summary of Calendar for Upcoming Proposed Delcath Rights Offering

GlobeNewswire July 31, 2018

Delcath Amends Phase 3 Ocular Melanoma Trial Protocol

GlobeNewswire July 27, 2018

Delcath Systems Announces Rights Offering and Backstop Commitment Ownership Date of August 1, 2018

GlobeNewswire July 16, 2018

Delcath Announces 100th Commercial CHEMOSAT Treatment Completed at Leiden University Medical Center, The Netherlands

GlobeNewswire July 9, 2018

Delcath Systems to Present at the 8th Annual LD Micro Invitational

GlobeNewswire May 29, 2018

Delcath’s CHEMOSAT Included in German Treatment Guidelines for Melanoma Liver Metastases

GlobeNewswire May 16, 2018

Delcath’s PHP Therapy Featured in Video Learning Session at the European Conference of Interventional Oncology 

GlobeNewswire May 14, 2018

Delcath Announces First Quarter 2018 Financial Results

GlobeNewswire May 10, 2018

Delcath Announces Initiation of Registrational Trial of Melphalan/HDS in Intrahepatic Cholangiocarcinoma

GlobeNewswire May 7, 2018

Delcath to Present at the RHK Capital 2018 Disruptive Growth and Healthcare Conference

GlobeNewswire May 4, 2018

Delcath Announces Another DSMB Recommendation for Phase 3 Focus Trial

GlobeNewswire May 3, 2018

Delcath Announces Ratio for Reverse Split Authorization

GlobeNewswire May 1, 2018

Delcath Announces Shareholder Approval of Consent Solicitation

GlobeNewswire April 9, 2018

Delcath’s PHP Therapy to be Featured in Video Training Session at European Conference of Interventional Oncology  

GlobeNewswire April 3, 2018

Summary of Recent Published Research on Delcath’s PHP Therapy Presented at Society of Surgical Oncology Annual Symposia

GlobeNewswire March 29, 2018

Delcath to Present at Oppenheimer 28th Annual Healthcare Conference

GlobeNewswire March 19, 2018

Delcath Announces 2017 Financial Results

GlobeNewswire March 16, 2018